Predictors of 6 month-mortality following intermediate-high and high risk pulmonary embolism

Abstract Funding Acknowledgements Type of funding sources: None. BACKGROUND Pulmonary embolism (PE) is the third most frequent cardiovascular disease and is associated with high mortality, during the admission and short-term follow-up. Due to Right Ventricular (RV) dysfunction or Pulmonary Hypertension (PH), also because anticoagulation's bleeding complications and PE may be the first manifestation of underlying cancer. Purpose To determine clinical and echocardiography characteristics and 6 month-mortality of patients with an intermediate-high or high PE admitted in the Acute Cardiovascular Care Unit (ACCU). Methods The present study is a retrospective analysis of 137 patients with intermediate-high and high risk PE admitted in our ACCU between May-2017 and May-2021. Clinical, biochemical and echocardiographic variables were analyzed on admission, prior to discharge and 6 month follow-up period. Mortality was evaluated at 6 months. Univariate logistic analysis was used to analyze markers associated with mortality. Results The majority were women 77 (56%), aged between 16-90 years. 78 (57%) had hypertension, 64(46%) Dyslipemia, 50(37%) obesity and 12 (9%) had previous cancer. On admission 76( 56%) patients consulted for dyspnea and 52(38%) for syncope. 81 (60%) presented respiratory failure (pO21. On admission echocardiography, 90 (66%) had RV dysfunction (TAPSE≤16mm), 120(89%) a dilated RV (basal RV/LV ratio>1.0) and PH was: 44 (36%) Mild, 48 (39%) Moderate and 22 (18%) Severe. Regarding first PE treatment patients received: 85 (62%) Heparin Sodium, 11 (8%) Systemic fibrinolysis, 31 (23%) Catheter-directed therapies and 10 (7%) LMWH. During the admission 6 (5%) patients suffer minor and 9 (7%) major bleeding. At discharge 101 (82%) improved RV function and 95 (82%) improved PH (None 62 (54 %), Mild 40 (35%), Moderate 11 (9%) and Severe 2 (2%)). In 6 months follow-up, 13(10%) died, 3(2%) were readmitted because of new PE and 4(3%) because of major bleeding. New cancer was diagnosed in 12(9%) patients. The majority (74%) were in NYHA-I. The risk of death at 6 months (Table 1) were significantly increased in diabetes patients (46% vs 16%,p=0.009), those in which RV dysfunction persisted (50% vs 8%,p=0.001), in case of major bleeding readmission (43% vs 0.8%,p=0.001) or those with an underlying cancer (57% vs 7%,p=0.001). Variables associated with 6